HCW Biologics (HCW Biologics) LT-Debt-to-Total-Asset : 0.22 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HCW Biologics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.22.

HCW Biologics's long-term debt to total assets ratio increased from Dec. 2022 (0.14) to Dec. 2023 (0.22). It may suggest that HCW Biologics is progressively becoming more dependent on debt to grow their business.

HCW Biologics LT-Debt-to-Total-Asset Historical Data

The historical data trend for HCW Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics LT-Debt-to-Total-Asset Chart

HCW Biologics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.14

0.22

HCW Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial												0.14	0.15	0.16	0.18	0.22

HCW Biologics LT-Debt-to-Total-Asset Calculation

HCW Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	6.304	/	28.514
	=	0.22

HCW Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	6.304	/	28.514
	=	0.22

HCW Biologics (NAS:HCWB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HCW Biologics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of HCW Biologics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

HCW Biologics (HCW Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 N Commerce Parkway, Miramar, FL, USA, 33025

Website

https://www.hcwbiologics.com

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong	director, officer: Chief Executive Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam	officer: Chief Financial Officer	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers	officer: SVP of Business Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene	director	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao	officer: VP of Development	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode	officer: See Remarks	C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd.	10 percent owner	16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057